First Clinical Experience with α-Emitting Radium-223 in the Treatment of Skeletal Metastases

Clinical Cancer Research - Tập 11 Số 12 - Trang 4451-4459 - 2005
Sten Nilsson1, Roy H. Larsen2, Sophie D. Fosså3, Lise Balteskard4, K. W. Borch2, Jan‐Erik Westlin5, G. Salberg2, Øyvind S. Bruland2,3
11Radiumhemmet, The Karolinska Hospital and Institute, Stockholm, Sweden;
22Algeta ASA,
33Department Group of Clinical Medicine, University of Oslo, Department of Oncology, The Norwegian Radium Hospital, Oslo, Norway;
44The University Hospital of Tromsø, Tromsø, Norway; and
55Mälarsjukhuset, Eskilstuna, Sweden

Tóm tắt

Abstract Purpose: The main goals were to study the safety and tolerability of the α-emitter radium-223 (223Ra) in breast and prostate cancer patients with skeletal metastases. In addition, pain palliation was evaluated. Experimental Design: Fifteen prostate and 10 breast cancer patients enrolled in a phase I trial received a single i.v. injection of 223Ra. Five patients were included at each of the dosages: 46, 93, 163, 213, or 250 kBq/kg and followed for 8 weeks. Palliative response was evaluated according to the pain scale of the European Organization for Research and Treatment of Cancer QLQ C30 questionnaire at baseline and at 1, 4, and 8 weeks after injection. Results: Weekly blood sampling during follow-up revealed mild and reversible myelosuppression with nadir 2 to 4 weeks after the injection. Importantly, for thrombocytes only grade 1 toxicity was reported. Grade 3 neutropenia and leucopenia occurred in two and three patients, respectively. Mild, transient diarrhea was observed in 10 of the 25 patients. Nausea and vomiting was more frequently observed in the highest dosage group. Serum alkaline phosphatase decreased with nadir averages of 29.5% in females and 52.1% in males. Pain relief was reported by 52%, 60%, and 56% of the patients after 7 days, 4, and 8 weeks, respectively. 223Ra cleared rapidly from blood and was below 1% of initial level at 24 hours. Gamma camera images indicated, in accordance with pretreatment 99mTc-MDP scans, accumulation of 223Ra in skeletal lesions. Elimination was mainly intestinal. Median survival exceeded 20 months. Conclusions: 223Ra was well tolerated at therapeutically relevant dosages. Phase II studies have therefore been initiated.

Từ khóa


Tài liệu tham khảo

Lipton A. Bone metastases in breast cancer. Curr Treat Options Oncol 2003;4:151–8.

Clohisy DR. Metastatic bone disease: Future directions. Clin Orthop 2003;415:S95–9.

Coleman RE. Skeletal complications of malignancy. Cancer 1997;80:1588–94.

Nielsen OS, Munro AJ, Tannock IF. Bone metastases: Pathophysiology and management policy. J Clin Oncol 1991;9:509–24.

Janjan N. Bone metastases: approaches to management. Semin Oncol 2001;28:28–34.

Osborn JL, Getzenberg RH, Trump DL. Spinal cord compression in prostate cancer. J Neurooncol 1995;23:135–47.

Falkmer U, Jarhult J, Wersall P, Cavallin-Stahl E. A systemic overview of radiation therapy effects in skeletal metastases. Acta Oncol 2003;42:620–33.

Ratanatharathorn V, Powers WE, Moss WT, Perez CA. Bone metastasis: Review and critical analysis of random allocation trials of local field treatment. Int J Radiat Biol Phys 1999;44:1–18.

Silberstein EB. Dosage and response in radiopharmaceutical therapy of painful osseous metastases. J Nucl Med 1996;37:249–52.

Serafini A. Therapy of metastatic bone pain. J Nucl Med 2001;42:859–906.

Resche I, Chatal JF, Pecking A, et al. A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer 1997;33:1583–91.

Silberstein EB. Systemic radiopharmaceutical therapy of painful osteoblastic metastases. Semin Radiat Oncol 2000;10:240–9.

Srivastava SC, Atkins HL, Krishnamurthy GT, et al. Treatment of metastatic bone pain with tin-117m stannic diethylenetriaminepentaacetic acid: a phase I/II clinical study. Clin Cancer Res 1998;4:61–8.

Hall EJ. Radiology for the radiologist. Ed. 5. Philadelphia: J.B. Lippincott Williams & Wilkins; 2000. p. 112–23.

Ritter MA, Cleaver JE, Tobias CA. High-LET radiations induce a large proportion of non-rejoining DNA-breaks. Nature 1977;266:653–5.

Withers HR, Mason K, Reid BO, et al. Response of mouse intestine to neutrons and gamma rays in relation to dose fractionation and division cycle. Cancer 1974;34:39–47.

Larsen RH, Murud KM, Akabani G, et al. 211At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation. J Nucl Med 1999;40:1197–203.

Henriksen G, Fisher DR, Roeske JC, Bruland ØS, Larsen RH. Targeting of osseous sites with α emitting 223Ra: comparison with β emitter 89Sr in mice. J Nucl Med 2003;74:252–9.

Hassfjell SP, Hoff P, Bruland ØS, Alstad J. Synthesis and biodistribution of a novel bone seeking α-emitting radiopharmaceutical. J Labelled Compds Radiopharm 1994;34:717–34.

Henriksen G, Bruland ØS, Larsen RH. Thorium and actinium polyphosphonate compounds as bone-seeking α particle-emitting agents. Anticancer Res 2004;24:101–6.

Henriksen G, Breistøl K, Bruland ØS, Fodstad Ø, Larsen RH. Significant antitumor effect from bone-seeking, α particle-emitting radium-223 demonstrated in an experimental skeletal metastases model. Cancer Res 2002;62:3120–5.

Engebråten O, Fodstad Ø. Site-specific experimental metastasis patterns of two human breast cancer cell lines in nude rats. Int J Cancer 1999;82:219–25.

Engebråten O, Sivam G, Juell S, Fodstad Ø. Systemic immunotoxin treatment inhibits formation of human breast cancer metastases and tumor growth in nude rats. Int J Cancer 2000;88:970–6.

Henriksen G, Hoff P, Alstad J, Larsen RH. 223Ra for endoradiotherapeutic applications prepared from an immobilized 227Ac/227Th source. Radiochim Acta 2001;89:661–6.

Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. Natl Cancer Inst 1993;85:365–76.

Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998;16:139–44.

Harrison GE, Carr TEF, Sutton A. Plasma concentration and excretion of calcium-47, strontium-85, barium-133 and radium-223 following successive intravenous doses to a healthy man. Nature 1966;209:526–7.

Zalutsky MR, Zhao XG, Alston KL, Bigner DD. High-level production of α-particle emitting (211)At and preparation of (211)At-labeled antibodies for clinical use. J Nucl Med 2001;42:1508–15.

Jurcic JG, Larson SM, Sgouros G, et al. Targeted α particle immunotherapy for myeloid leukemia. Blood 2002;100:1233–9.

Guise TA, Mundy GR. Cancer and bone. Endocr Rev 1998;19:18–54.

Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889;1:571–3.

Sciuto R, Festa A, Rea S, et al. Effects of low-dose cisplatin on 89Sr Therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med 2002;43:79–86.

Smeland S, Erikstein B, Aas M, Skovlund E, Hess SL, Fossa SD. Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: Result of a double-blind randomized study. Int J Radiat Biol Phys 2003;56:1397–404.

Saad F, Allen AR, Hulting SM, Isaacson JD, Sleep DJ. ASCO annual meeting 2004; Abstract No: 4655 [abstract on the internet]. Available from: http://www.asco.org/ac/1,1003,_12-002636-00_18-0026-00_19-001587,00.asp.

Nekolla EA, Kreisheimer M, Kellerer AM, Kuse IM, Gossner W, Spiess H. Induction of malignant bone tumors in radium-224 patients: risk estimates based on the improved dosimetry. Radiat Res 2000;153:93–103.

Wick RW, Nekolla EA, Gøssner W, Kellerer AM. Late effects in ankylosing spondylitis patients treated with 224Ra. Radiat Res 1999;152:S8–11.

Tiepolt C, Grunning T, Franke WG. Renaissance of 224Ra for the treatment of ankylosing spondylitis: clinical experiences. Nucl Med Commun 2002;23:61–6.

Lassmann N, Nosske D, Reiners C. Therapy of ankylosing spondylitis with 224Ra-radium chloride: dosimetry and risk considerations. Radiat Environ Biophys 2002;41:173–8.

Nekolla EA, Kellerer AM, Kuse-Isingshulte M, Eder E, Spiez H. Malignancies in patients treated with high doses of radium-224. Radiat Res 1999;152:S3–7.

Porter AT, McEvan AJB, Powe JE, et al. Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Biol Phys 1993;25:805–13.

Palmedo H, Manka-Waluch A, Albers P, et al. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: randomized phase II trial with the new high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol 2003;21:2869–75.

Tu SM, Millikan RE, Mengistu B, et al. Bone targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 2001;357:336–41.

Thông tin
Thông tin xuất bản

Clinical Cancer Research

Tập 11 Số 12

4451-4459

Thông tin tác giả